# EDGAR Filing Document

**Accession Number:** 0001853904
**File Stem:** 0001380106-25-000185
**Filing Date:** 2025-8
**Character Count:** 10315
**Document Hash:** 9e05398e30b6849664d21d98ba73fef3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001380106-25-000185.hdr.sgml**: 20250819

**ACCESSION NUMBER**: 0001380106-25-000185

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250819

**DATE AS OF CHANGE**: 20250819

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RAPID MICRO BIOSYSTEMS, INC.
- **CENTRAL INDEX KEY:** 0001380106
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 208121647
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92824
- **FILM NUMBER:** 251233201

**BUSINESS ADDRESS:**
- **STREET 1:** 25 HARTWELL AVENUE
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421
- **BUSINESS PHONE:** 978-349-3200

**MAIL ADDRESS:**
- **STREET 1:** 25 HARTWELL AVENUE
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RAPID MICRO BIOSYSTEMS INC
- **DATE OF NAME CHANGE:** 20061103
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Spignesi Robert G. Jr.
- **CENTRAL INDEX KEY:** 0001853904

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**MAIL ADDRESS:**
- **STREET 1:** C/O RAPID MICRO BIOSYSTEMS, INC.
- **STREET 2:** 1001 PAWTUCKET BOULEVARD WEST, SUITE 280
- **CITY:** LOWELL
- **STATE:** MA
- **ZIP:** 01854

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**RAPID MICRO BIOSYSTEMS, INC.**

*(Name of Issuer)*

**Class A Common Stock, $0.01 par value per share**

*(Title of Class of Securities)*

**75340L104**

*(CUSIP Number)*

**Robert G. Spignesi, Jr.**<br>Rapid Micro Biosystems, Inc.<br>25 Hartwell Avenue<br>Lexington MA 02421<br>978-349-3200

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**03/28/2024**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **75340L104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**SPIGNESI ROBERT G JR** | Name of reporting person<br>**SPIGNESI ROBERT G JR** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**2647256.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**2647256.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2647256.00** | Aggregate amount beneficially owned by each reporting person<br>**2647256.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.3%** | Percent of class represented by amount in Row (11)<br>**6.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Class A Common Stock, $0.01 par value per share

**(b) Name of Issuer:**
RAPID MICRO BIOSYSTEMS, INC.

**(c) Address of Issuer's Principal Executive Offices:**
25 Hartwell Avenue, Lexington, MA, 02421

**Item 4. Purpose of Transaction**

The information set forth or incorporated by reference in Items 3 and 6 of this Statement is incorporated by reference into this Item 4.

The Reporting Person intends to continuously review his investment in the Issuer and may in the future determine (1) to acquire additional securities of the Issuer, through open market purchases, private agreements or otherwise, (2) to dispose of all or a portion of the securities of the Issuer owned by him or (3) to take any other available course of action. Notwithstanding anything contained herein, the Reporting Person specifically reserves the right to change his intention with respect to any or all of such matters. In reaching any decision as to his course of action (as well as to the specific elements thereof), the Reporting Person currently expects that he would take into consideration a variety of factors, including, but not limited to, the following: the Issuer's business and prospects; other developments concerning the Issuer and its business generally; other business opportunities available to the Reporting Person; developments with respect to the business of the Reporting Person; changes in law and government regulations; general economic conditions; and money and stock market conditions, including the market price of the securities of the Issuer.

The Reporting Person is President and Chief Executive Officer and a member of the Board of Directors of the Issuer and, accordingly, in such capacity, may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Subject to the Issuer's Insider Trading Policy, the Reporting Person may from time to time buy or sell securities of the Issuer as appropriate for his personal circumstances.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information set forth in rows 7 through 13 of the cover page to this Schedule 13D is incorporated by reference.

The Reporting Person beneficially owns an aggregate of 2,647,256 shares of Class A Common Stock, which consists of (i) 493,931 shares of Class A Common Stock held directly by the Reporting Person, (ii) 10 shares of Class A Common Stock issuable to the Reporting Person upon exercise of warrants exercisable within 60 days of this Statement and (iii) 2,153,315 shares of Class A Common Stock issuable to the Reporting Person upon exercise of stock options exercisable within 60 days of this Statement. The foregoing excludes 1,197,990 shares of Class A Common Stock underlying equity awards that are currently unvested and are not substantially certain to vest within 60 days of this statement.

**(b)**
The 2,647,256 shares of Class A Common Stock beneficially owned by the Reporting Person represents approximately 6.3% of the outstanding shares of Class A Common Stock. The percent of class was calculated based on (i) 39,710,799 shares of Class A Common Stock outstanding, as reported by the Issuer to the Reporting Person, plus (ii) 2,163,315 shares of Class A Common Stock underlying stock options and/or warrants held by the Reporting Person that are exercisable within 60 days, which are deemed outstanding pursuant to SEC Rule 13-3(d)(1)(i).

**(c)**
Between July 8, 2025 and July 14, 2025, the Reporting Person acquired an aggregate of 125,722 shares of Class A Common Stock upon satisfaction of performance criteria underlying previously granted restricted stock units ("RSUs") subject to performance-based vesting conditions.

In connection with tax withholding obligations relating to the vesting and settlement of such RSUs, the Reporting Person sold an aggregate of 57,443 shares of Class A Common Stock as follows: (i) 10,824 shares sold on July 8, 2025 at a price per share of $3.5127; (ii) 11,247 shares sold on July 9, 2025 at a price per share $3.5103; (iii) 11,617 shares sold on July 10, 2025 at a price per share of $3.398; (iv) 11,874 shares sold on July 11, 2025 at a price per share of $3.3265; and (v) 11,881 shares sold on July 14, 2025 at a price per share of $3.323. The sales were effected on the open-market through broker-assisted transactions.

In addition, during the 60 days preceding this statement, the Reporting Person acquired beneficial ownership of 38,757 shares of Class A Common Stock underlying equity awards subject to vesting, as further described in Item 6 below.

Except as otherwise described in this Item 5(c), the Reporting Person has not effected any transactions in the Issuer's Class A Common Stock during the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information contained in Item 3 is incorporated herein by reference.

The Reporting Person is and will be entitled to receive compensation and other benefits as President and Chief Executive Officer of the Issuer. In such capacity, he may also be granted equity awards with respect to the Issuer's Class A Common Stock from time to time. The Reporting Person currently holds (i) 731,871 RSUs subject to time-based and performance-based vesting, each representing the contingent right to receive one share of Class A Common Stock, and (ii) stock options to purchase an aggregate of 2,619,434 shares of Class A Common Stock at exercise prices ranging between $0.75 and $10.85 per share. The equity plans under which such awards have been granted and the form of award agreements representing such equity awards are filed as Exhibits 99.1 and 99.2 hereto, and are incorporated by reference into this Item 6 in their entirety.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** SPIGNESI ROBERT G JR

**Signature:** /s/ Robert G. Spignesi, Jr.

**Name/Title:** Robert G. Spignesi, Jr.

**Date:** 08/19/2025